Session 6 Flashcards

1
Q

What is ‘Spirometry’

A
  • ‘Spirometry’ (Latin) = the measuring of breath
  • The spirometer records the volume of air that is breathed in and out
  • and generates tracings of air flow (i.e. pneumotachographs)
  • Tracings used to calculate: – vital capacity, tidal volume – the flow rate of air movement
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Reasons for Pulmonary Function Tests

A
  • Diagnosis -Tests are rarely diagnostic on their own – Results taken together with history and examination
  • Patient assessment -Most usual reason for tests – Serial changes – Response to therapy – Assessment for compensation – Pre-surgical assessment
  • Research purposes – Epidemiology – Study of growth and development – Investigation of disease processes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Do we take spirometry readings standing or seated?

A

• FVC standing> FVC seated

– BUT high intrathoracic pressure can result in reduced cardiac output and cerebral blood flow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

3 types of graph produced using spirometry?

A

Tracings, Graphs Flow, Volume Loops

insert slide 6 lec 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Movements of the TRACE

A
  • The classic presentation of the traces from these recordings is therefore:
  • INSPIRATION as an upward deflection
  • EXPIRATION as a downward deflection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Draw a spirogram trace and label it. How are the values calculated?

A

insert slide 10 lec 1

  • Lung Capacities – Inspiratory capacity =
  • VT + IRV – FRC – VT – VC
  • Inspirational capacity = – VT + IRV
  • Functional Residual Capacity = – ERV + RV
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How do we get from a spirogram (volume-time trace) to a volume-time graph?

A

panopto

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Forced flow-volume measurements show us?

A

• How much air can the subject blow out? – can be reduced in restrictive disorders, – or if there is airway narrowing precipitating early airway closure (e.g. asthma or CF) • How fast is the air expelled? – can be reduced with airway narrowing. • Pattern of change in flow-volume curve (insp& exp) can indicate site of obstruction • Response to treatment (e.g. β2agonist) • Change with age or growth • Progression of disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is FVC, FEV1, PEF and why is FEV1 useful

A

FVC: Maximal amount of air that the patient can forcibly exhale after taking a maximal inhalation

FEV1: Volume exhaled in the first second

Peak expiratory flow (PEF): Maximal speed of airflow as the patient exhales

FEV1 is the most reproducible flow parameter and is especially useful in diagnosing and monitoring patients with obstructive pulmonary disorders (eg, asthma, COPD).

picture from slide 14

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Nomogram for predicting FVC

A

Forced vital capacity (FVC) – The measured value is compared to that of healthy people of the same • gender, • age and • height slide 15 lec 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

The time- volume graph

A

Patient inspires to vital capacity Rapid forced expiration • Convention shows expiration as a downward defection on a spirometry trace: • This is a graph volume (L) expired against time • Follows normal graph conventions inser pic from slide 16 lec 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Volume-time plot of maximal forced expiration

A

ue panopto slide 17 lec 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Volume-Time graphs in obstructive disease (Asthma, COPD)

A
  • FVC is not markedly reduced
  • (if given sufficient time to completely breathe out)
  • Narrowed airways reduces the speed at which air can be breathed out.
  • Fraction of air expelled during 1st second (FEV1 /FVC) is markedly reduced.
  • Typical pattern in obstructive airways disease: – FVC nearly normal – FEV1 markedly reduced – The FEV1 /FVC ratio < 70%

slide 18 lec 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Volume-Time graphs in restrictive disease (lung fibrosis)

A

Volume-Time graphs in restrictive disease (lung fibrosis) • FVC is markedly reduced (lungs stiff, cannot be expanded adequately) • However, the speed at which air can be breathed out is normal (because no narrowing of airways) • the fraction of air expelled during 1st second is normal or even greater than normal • The typical pattern in restrictive airways disease: – A Low FVC – Low FEV1 – But FEV1 /FVC ratio ≥ 70% slide 19 lec 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How do we get from a spirogram (volume-time trace) to a flow-volume loop?

A

use panopto slide 21 lec 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Ho might the flow volume look normally compared to COPD, Fixed-extra thoracic obstruction, during a cough, restrictive lung disease and upper airway obstruction? and why?

A

slide 23 lec 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How do obstructive diseases differ on a flow volume loop compared to restrictive disease and then mixed disease

A

slide 30 lec 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is bronchiectasis?

A

DEFINITION: Chronic IRREVERSIBLE dilatation of one or more bronchi – it is a pathological condition that can be caused by many diseases or be idiopathic- resulting in abnormally enlarged bronchi – These deformed bronchi exhibit poor mucus clearance and there is predisposition to recurrent or chronic bacterial infection

  • AETIOLOGY: variety of underlying causes, with a common underlying mechanism of of chronic inflammation • Inflammation causes destruction of the elastic and muscular components of the bronchial wall and peribronchial fibrosis
  • RADIOLOGICAL FINDINGS • CXR - usually abnormal but inadequate in the diagnosis or quantification of bronchiectasis/ bronchial dilatation – Gold standard diagnostic investigation = CT - specifically High Resolution CT
  • We find -bronchial dilatation bigger than the adjacent blood vessel, bronchial wall thickening
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How is bronchiectasis signified on a CT?

A

Signet Ring Signdilated bronchus and accompanying pulmonary artery branch are seen in cross-section. healthy lung bronchus slightly Smaller than artery whereas in bronchiectasis, the bronchus is markedly dilated > artery slide 3 lec 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What do you notice about this pitients lungs insert diagram from slide 4 lec 2

A

Gross pathologic lung specimen from a patient with bronchiectasis. Notice the small pulmonary artery abutting the much larger dilated bronchus (arrow), both of which are seen on cross- section

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Clinical symptoms of bronchiectasis?

A

Very Common: • Chronic cough • Daily sputum production – can vary in quantity, colour and consistency Common: • Breathlessness on exertion • Intermittent haemoptysis • Nasal symptoms • Chest Pain • Fatigue Less Common: • Wheeze Symptoms not very specific – history and risk factors key to Dx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Bronchiectasis – what are the clinical signs?

A

• Pulse oximetry may reveal hypoxaemia in advanced cases of bronchiectasis • Fever relatively common - More than half of patients with bronchiectasis will have recurrent episodes of fever • Haemoptysis - present in about 50% of patients - usually mild • Fine crackles (rales) • High-pitched inspiratory squeaks • Rhonchi • Sometimes can hear both crackles & wheezing - Lungs sounds from CF patient w/ bronchiectasis • Systemic signs - a history of weight loss common • Clubbing of the digits is less common

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Causes of bronchiectasis?

A

• Post infective– whooping cough (pertussis), TB • Immune deficiency– Hypogammaglobulinaemia • Mucociliaryclearance defects– Cystic fibrosis, primary ciliary dyskinesia, Young’s syndrome (triad of bronchiectasis, sinusitis, and reduced fertility), Kartagener syndrome (triad of bronchiectasis, sinusitits, and situs inversus) • Idiopathic • Alpha-1-antitrypsin deficiency • Obstruction – foreign body, tumour, extrinsic lymph node • Toxic insult – gastric aspiration (particularly post lung transplant), inhalation of toxic chemicals/gases • Allergic bronchopulmonary aspergillosis • Secondary immune deficiency – HIV, malignancy • Rheumatoid arthritis • Associations – inflammatory bowel disease; yellow nail syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Bronchiectasis Common Organisms - How is it a vicious cycle?

A

• Haemophilus influenzae • Pseudomonas aeruginosa • Moraxella catarrhalis • Stenotrophomonas maltophilia • Streptococcus pneumoniae • Fungi – aspergillus, candida • Mycobacteria tuberculosis • Nontuberculous mycobacteria (NTM) • Less common - Staphylococcus aureus Bronchial dilation leads to mucous accumulation, impaired ciliary function and increased risk infection; Infection leads to inflammation and loss bronchial elastic fibres and smooth muscle –leads to more dilatation!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

How might a patient with possible bronchiectasis present?

A

• History of “asthma” (particularly lifelong )without any great objective evidence – such as reversible airway obstruction on spirometry– also in asthma no inspiratory squeaks and crackles • History of “COPD” but diminished breath sounds, characterising COPD, are not found & different risk factors • BUTif they do have a history of – Severe chest infection earlier in life (bacterial, viral or atypical) – Lifelong chest infections ? genetic cause – Recurrent chest infections ?immunodeficiency – Recurrent sinus infections since childhood? ? Ciliary dysfunc, • Sputum culture positive for common organisms such as haemophilus or pseudomonas or atypical mycobacterium • Inflammatory bowel disease, rheumatoid arthritis – also associated with bronchiectasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Why is early diagnosis of bronchiectasis important?

A

early diagnosis and treatment of predisposing underlying disorders may impede disease progression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

How are Pulmonary function tests used to diagnose bronchiectasis?

A

• Initial and follow up spirometry is recommended with most surgery visits – diagnosis and follow up lung function • Obstructive airways disease component may be evidenced by reduced forced expiratory volume (FEV1) or an FEV1/forced vital capacity (FVC) ratio of <70% • Full pulmonary function testing may show an elevation of RV/TLC ratio consistent with air trapping. • Diffusing capacity for carbon monoxide (DLCO) may be reduced in severe disease • Question: We all remember diffusing capacity is inversely related to the distance the gas has to travel – so, since there is marked thickening of the bronchial walls why isn’t diffusing capacity reduced in early disease?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Make a table showing the differences between chronic bronchitis, bronchiectasis, asthma, emphysema and bronchiolitis

A

slide 8

29
Q

Bronchiectasis Management

A

• PHYSIO / AIRWAYS CLEARANCE –Daily airway clearance is essential for treatment success • Sputum sampling –routine culture and NTM • Exclude immunodeficiency / treat identifiable causes • Consider long-term therapies at future visits • Annual Flu & routine vaccinations against Haemophilus influenzae and Streptococcus pneumoniae • An established MDT is key • Management plan for infective exacerbation

30
Q

Defining an exacerbation n bronchiectasis

A

• How do we define “exacerbation” in bronchiectasis? • Recent international expert consensus……….. A person with bronchiectasis with a deterioration in 3 or more key symptoms for at least 48 hours: • Cough • Sputum volume and / or consistency • Sputum purulence • Breathlessness and / or exercise tolerance • Fatigue • Haemoptysis

31
Q

What is the most common identifiable cause of bronchiectasis? how has survival rates for this condition changed?

A

Cystic Fibrosis • In the 1950s, median life expectancy for patients with cystic fibrosis was a few months • In the 1990’s median life expectancy was late teens • Today ~𝟒𝟎𝐲/𝐨! Tremendous improvement in life expectancy have been achieved by understanding the importance of –Augmenting airway clearance – 2-3x/day –Aggressively treating infection, –Correcting nutrition deficits –New drug treatments targeting underlying molecular defect?

32
Q

What cystic fibrosis?

A

• Autosomal recessive disorder • 1 in 2,500 in the UK are born with CF – CF mutations most common in populations with northern European ancestry where the predominant mutation is Phe508del (also known as F508del) – deletion of Phenylalanine at position 508 of the polypeptide chain • CF caused by mutations of gene located on long arm chromosome 7 that lead to abnormal function of an epithelial chloride channel the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) –which has a key role in maintaining lung epithelial function • Also important in normal epithelial function other body organs; important comorbidities caused by epithelial cell dysfunction occur in the pancreas (malabsorption), liver (biliary cirrhosis), sweat glands (heat shock), and vas deferens (infertility)) • Cystic Fibrosis Cellular Defect 1/3 • Cystic Fibrosis Cellular Defect 2/3 • Cystic Fibrosis Cellular Defect 3/3 Molecular basis Cystic Fibrosis I • CFTR is a transmembrane protein that transports chloride and bicarbonate & also regulates the Epithelial Sodium Chanel (ENAC) • CFTR enables Cl to be transported out of cells into airways - the transport of chloride ions helps control the movement of water • CFTR also regulates sodium reabsorption into cells • Therefore CFTR plays a critical role in the hydration of the mucus at the surface of the airway track • Defective ion transport mediated by CFTR reduces airway surface liquid hydration, which leads to thick & sticky mucous & impairs muco-ciliary clearance • Over 2000 mutations related to CTFR gene (though not all pathogenic) • Mutations have different effects on the – Manufacture of CFTR protein, – Transportation of CFTR – CFTR processing function, – CFTR stability at the cell membrane (More on mutations to follow later in lecture)

33
Q

How is cystic fibrosis diagnosed?

A

One or more of the characteristic phenotypic features • Or a history of CF in a sibling • Or a positive newbornscreening test result And • An increased sweat chloride concentration (> 60 mmol/l) –SWEAT TEST • Or identification of two CF mutations –genotyping – may need EXTENDED GENOTYPING

34
Q

Main CF Clinical Presentations (“classic” CF)

A
  1. Meconium ileus • In 15-20% of newborn CF infants the bowel is blocked by the sticky secretions. There are signs of intestinal obstruction soon after birth with bilious vomiting, abdominal distension and delay in passing meconium. 2. Intestinal malabsorption • Over 90% of CF individuals have intestinal malabsorption. In most this is evident in infancy. The main cause is a severe deficiency of pancreatic enzymes. 3. Recurrent chest infections 4. Newborn screening
35
Q

Late Diagnosis of cystic fibrosis?

A

• Cystic fibrosis is usually identified following newborn screening or during the first few years of life - people diagnosed after 20 years of age usually have a mutation associated with residual CFTR function – Or heterozygous CFTR mutations – one severe + one mild • Increasingly recognized that some variants of CF may present in adults – classified as “Atypical CF” • Need a high index of suspicion to diagnose • Consider in cases of recurrent “idiopathic pancreatitis” , recurrent sinusitis & lung infections, infertility, allergic bronchopulmonary aspergillosis (IgE hypersensitivity reaction to Aspergillus species)

36
Q

CF Complications

A

LUNGS • Bronchiectasis • Pneumothorax • ABPA • Haemoptysis • Respiratory failure NASAL / UPPER RESP TRACT • Chronic sinusitis • Nasal polyposis PANCREAS • DM - CFRD • Pancreatic insufficiency GUT • Distal Intestinal Obstruction Syndrome (DIOS) • oesophageal reflux / oesophagitis LIVER • Chronic liver disease • Portal Hypertension BILIARY TREE • Gallstones HEART • Cardiac failure JOINTS & BONES • Arthritis • Osteoporosis REPRODUCTIVE TRACT • Male infertility • Congenital bilateral absence of vas deferens (CBAVD) Pseudomonas aeruginosa colonisation and infection particularly virulent pathogen in CF

37
Q

CF Lifestyle advice

A

•No smoking •Avoid other CF patients •Avoid friends / relatives with colds / infections •Avoid jacuzzis (pseudomonas) •Clean and dry nebulisers thoroughly •Avoid stables, compost or rotting vegetation – risk of aspergillus fumigatus inhalation •Annual influenza immunisation •Sodium chloride tablets in hot weather / vigorous exercise

38
Q

CF Clinical Management

A

• Complex - led by CF Specialist Centres / MDT’s • Holistic care / Multisystem (organ) focus • Up to date pneumococcal and haemophilus influenza vaccinations and annual influenza • Key is maintaining lung health (chest physio, infection management) • Optimal nutritional state – pancreatic status, vitamin status, weight / BMI

39
Q

Role of nutrition in cystic fibrosis

A

• CF mostly recognized for its pulmonary morbidity, but earliest manifestations disease related to gastrointestinal and nutritional derangements • Several factors contribute to impaired nutritional status in cystic fibrosis – Pancreatic insufficiency, – Chronic malabsorption, – Chronic inflammation leading to increased energy expenditure – Increased energy requirements of breathing – Suboptimal nutrient intake related to impaired taste (sinuses), fatigue,I nflammatorymediated anorexia • Interestingly, nutritional status plays an important role in the progression of the pulmonary disease –better nutritional status associated with better lung function • In one study nocturnal gastrostomy tube supplementation was associated with improved FEV1 –this appeared to be related to preservation of muscle mass • In several intervention trials in children, prolonged nutritional therapy led to improvements in – pulmonary function parameters, – measures of respiratory muscle strength, – hospitalisation rates, – gains in exercise capacity Suggestion that nutritional therapy supports lung growth and development

40
Q

Molecular basis underlying Cystic Fibrosis II –categorisation of defects

A

CFTR mutations can be divided into six classes according to their effects on protein function • Range of mutation effects from • No protein production, • Protein made but never gets to the cell membrane, • Protein gets to the membrane but doesn’t work at all • Protein made but only partially active • Protein expressed at gene level but substantial reduction in mRNA or protein, or both, synthesis • Protein gets to membrane but partially unstable • Medications now being developed that target underlying disease mechanisms –not just complications

41
Q

What is Orkambi

A

• Trade name for two drugs • lumacaftor and ivacaftor • Lumacaftor – CFTR chaperone during protein folding increases the number of CFTR proteins that are trafficked to the cell surface – helps in people with Phe508del-most common mutation • Ivacaftor - CFTRpotentiator, improves the transport of chloride through the ion channel by binding to the channels directly and increasing the probability that the channel is open- helps in people with G551D mutation4–5% cases of cystic fibrosis • Interestingly – combining these two drugs synergistically helps people with the Phe50del mutation

42
Q

What is an X-ray

A

An electromagnetic wave of high energy and very short wavelength, which is able to pass through many materials opaque to light  A photographic or digital image of the internal composition of the body, produced by X-rays being passed through the body part and being absorbed to different degrees by different tissues  This is displayed as levels of contrast on a grey scale (black to white)

43
Q

What is the radiation dose of a chest x-ray?

A

What does this mean?  Ave UK background dose = 2.7 mSv/year  Thus x3 days worth of background radiation  But if living in Cornwall = 7.8 mSV  1 in a million lifetime additional risk of fatal cancer  IRR allows workers upto 20 mSV/year  Ave nuclear worker = 0.18 mSV  Transatlantic flight = 0.08 mSv  100g bag of brazil nuts = 0.01 mSv

44
Q

X-ray projection – why is it important?

A

use panopto slide 8

45
Q

What needs to be seen on a chest x ray

A

 1st rib  Lateral margin of ribs  Costophrenic angle  Alignment of:  Spinous process and  Clavicles

46
Q

How are lung volumes seen on a chest x-ray?

A

 Inspiratory phase  Normal  5th to 7th anterior ribs at MCL  Problems with incomplete inspiration:  Big heart  Increased lung markings  Exaggerated expansion  Obstructive airways disease use panopto

47
Q

What is penetration (X-rays)

A

 Degree to which the x-rays have passed through the body  Adequate penetration  Vertebrae just visible through heart  Complete left hemidiaphragm is visible  Digital manipulation often negates this

48
Q

What is an artefact (X-rays)

A

 External/iatrogenic material which obstructs view  Clothes  Buttons – beware!  Hair  Surgical/vascular lines  Pacemaker

49
Q

Label the: 1. Trachea 2. Hila 3. Lungs 4. Diaphragm 5. Heart 6. Aortic knuckle 7. Ribs 8. Scapulae 9. Breasts 10. Bowel gas

A

insert mage from slide 18 lec 3

50
Q

Describethe lobes of the lungs

A

slide 21 lec 3

51
Q

Where are the costophrenic angles and costophrenic recesses?

A

slide 24

52
Q

how might a stomach buble be seen on a chest X-ray

A

slide 25

53
Q

Mediastinal contours on chest x-ray

A

slide 27

54
Q

How to evaluate a chest X-ray

A

 Systematic ABC approach  Patient demographics  Projection  Adequacy  Airway  Breathing  Circulation  Diaphragm / Dem bones  Review areas

55
Q

Define Pulmonary ventilation

A

The movement of air into (inhalation) and out of the lungs (exhalation) – the total amount of air moving in and out of the lungs

56
Q

Define Pulmonary gas exchange

A

the diffusion of oxygen from the lungs into the blood, and the diffusion of carbon dioxide from the blood into the lungs

57
Q

Define Pulmonary perfusion

A

the flow of blood through the pulmonary capillaries surrounding the alveoli – typically expressed as Q ml/min

58
Q

Define ALVEOLAR ventilation

A

ALVEOLARventilation is the amount of air reaching alveoli in a given amount of time– function of the tidal volume, the amount of air in the anatomical dead space, and the respiratory rate –typically expressed as V – Example: someone breathing 14 times a minute, with a tidal volume of 500 ml, and anatomical dead space of 150 ml will have an – alveolar ventilation- of 14 /minute ×(500 ml air -150 ml air) = 4900 ml air/minute = V

59
Q

What is V/Q

A

When discussing ventilation/perfusion often referred to as V/Q

60
Q

Normal physiology of lung ventilation and perfusion

A

slide 4 lec 4

61
Q

Ventilation and perfusion has to be matched throughout the lung. How is this achieved?

A

Gas exchange optimal when: – V/Q ratio of individual alveolar units ≈ 1 • 300 million alveoli - may have widely differing amounts of ventilation and of perfusion. • Ideally, – Alveoli with ventilation should have perfusion – Alveoli with ventilation should have perfusion • When pulmonary capillary PaO2 is low, hypoxic vasoconstriction of pulmonary arterioles occurs - this diverts blood to better ventilated alveoli • When alveolar PA CO2 is low, bronchoconstriction occurs – This diverts air to better perfused lung • BUT • This process is not 100% efficient, so in some disease states, poorly ventilated alveoli still have significant perfusion – this is what is meant by ventilation-perfusion MISMatch

62
Q

Gas composition in a normal alveolus

A

Alveolar gas composition is steady at: PAO2= 13.3 kPa PACO2= 5.3 kPa Alveolar gas composition is steady because amount of O2 (ml/min) brought in by ventilation= amount of O2 (ml/min) diffusing into the blood and amount of CO2 removed by ventilation = amount of CO2 diffusing from blood into the alveolus There is equilibrium between the partial pressures of gas in the air and gas in the liquid (blood) slide 7 lec 4

63
Q

Consequences of Inadequate Ventilation of an alveolar unit

A

Inadequate ventilation for perfusion (V/Q <1) – PACO2 rises – PAO2 falls, – A new steady state established – diffusion continue at this new level – Blood equilibrates to the new alveolar PAO2 &PACO2

64
Q

V/Q mismatch with V/Q ratio <1

A

Some causes: – Asthma (airway narrowing – not uniform throughout lungs – COPD early stages – not uniform throughout lungs – Pneumonia -acute inflammatory exudate in affected alveoli – RDS in newborn -some alveoli not expanded and not uniform – Pulmonary oedema -fluid in alveoli - not uniform throughout lungs V/Q mismatch is the commonest mechanism causing hypoxia.

65
Q

What will be the PO2 in the mixed blood? Will it be normal? Lower than normal? Or higher than normal? By how much? slide 10 lec 4

A

•Need to consider more than just the PO2 values. •Determined by interaction of O2 with Hb as well. •Need to consider the Oxy-Hb dissociation curve . •So let’s review Oxy-Hb dissociation curve If a gas reacts with a substance within a liquid e.g. O2 binding to haemoglobin (Hb) -in addition to dissolving then this reaction must complete before equilibrium is reached and partial pressure is established – the oxygen binding to Hb does NOT contribute to pO2 in the blood • O2 enters plasma & dissolves in plasma, • dissolved O2 enters RBC to bindto Hb • Process continues till Hb fully saturated (each Hb molecules binds 4 O2 molecules) • After Hb is fully saturated, O2 continues to dissolve till equilibrium is reached • Total CONTENT O2 = Σ(sum) of dissolved and Hb bound oxygen • Necessary to have carrier because O2 not highly soluble BUT-once carrier is fully saturated –CAN’T carry any more no matter how much O2 is present! Corresponding O2 content in blood (in ml/L) –NB- most O2 content in blood associated with Hb Graph demonstrates how changes in the partial pressure of oxygen (PO2) influence oxygen (O2) binding to, and dissociation from, haemoglobin (Hb). PO2 on X axis represents value of PO2 in the alveoli of the lungs under resting conditions (resting respiratory rates) (red arrow) – converting to kPa 100 mmHg= 13.3 kPa NB:To convert mm Hg to kPa Multiple mmHg by 0.133322 As pO2 increases from 10.6 kPa (80 mmHg) to 13.3 kPa9 (100 mmHg) haemoglobin saturation markedly increases by greater than 20%

66
Q

Graph showing relationship between PCO2 and total CO2 content in blood

A

Ø Relatively straight line in the physiological range pCO2 i.e. there is a linear relationship between pCO2 and blood total content CO2 @ 4-6kPa Ø This is because CO2 Is highly soluble in blood Ø Unlike O2 it doesn’t require a carrier molecule – remember O2 carrier molecule is Hb Ø This explains why CO2 in blood is directly proportional to alveolar minute ventilation while O2 is NOT – after a certain point can’t load more haemoglobin with O2 no matter how high pO2

67
Q

What is the PO2 and PCO2 in the mixed blood –blood from poorly ventilated but still perfused lung combined with blood from well ventilated and perfused lung ? (Assume equal volumes of blood returning from the affected and unaffected areas)

A

slide 16 lec 4 17 too

68
Q

What is the effect of hyperventilation?

A

slide 18 lec 4 19 too